US3354218A - Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one - Google Patents

Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one Download PDF

Info

Publication number
US3354218A
US3354218A US279617A US27961763A US3354218A US 3354218 A US3354218 A US 3354218A US 279617 A US279617 A US 279617A US 27961763 A US27961763 A US 27961763A US 3354218 A US3354218 A US 3354218A
Authority
US
United States
Prior art keywords
trimethyl
cyclohexen
buten
methoxy
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US279617A
Inventor
Surmatis Joseph Donald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to US279617A priority Critical patent/US3354218A/en
Application granted granted Critical
Publication of US3354218A publication Critical patent/US3354218A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C07C403/16Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms not being part of —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • the present invention relates to a novel process for the preparation of zeaxanthin dimethyl ether.
  • Zeaxanthin dimethyl ether is useful as a coloring agent for coloring feedstuifs and foodstuffs. It is a known compound, having been prepared from natural zeaxanthin.
  • the present process is a process for its total synthesis.
  • the instant process is carried out by first treating fi-ionone (I) with N-bromosuccinimide, followed by dehydrobromination of the reaction product with a dehydrobrominating agent such as dimethylaniline, pyridine, or other organic bases as diethylaniline, quinoline, etc. to form 4-(2, 6,6-trimethyl 1,3-cyclohexadien-l-yl)-3-buten-2-one (II).
  • II is treated with methyl sulfate and methyl alcohol to form 4* (2,6,6-trimethy1-4-methoxy- 1 -cyclohexen-1 -yl -3-buten- 2-one (III).
  • an acid hydrolyzing agent e.g., a dilute solution of a mineral acid such as HCl, H o-phosphoric acid, etc., or a strong organic acid, preferably acetic acid in the presence of sodium acetate to form 6 (2,6,6 trimethyl 4-methoxy-l-cyclohexen-l-yl)-4- methyl-2,4-hexadien-l-al (V).
  • V is treated with triethylorthoform-ate and phosphoric acid followed by treatment with zinc chloride in ethyl acetate and ethyl propenyl ether and the resulting product is hydrolyzed with an acid hydrolyzing agent, e.g., a dilute solution of a mineral acid such as HCl, H 80 o-phosphoric acid, etc., or a strong organic acid, preferably acetic acid in the presence of sodium acetate, to form 8-(2,6,6-trimethy1-4-meth0Xyl cyclohexen 1 yl)-2,6-dimethyl-2,4,6-octatriene-l-al (VI).
  • an acid hydrolyzing agent e.g., a dilute solution of a mineral acid such as HCl, H 80 o-phosphoric acid, etc., or a strong organic acid, preferably acetic acid in the presence of sodium acetate, to form 8-(2,6,6-trimeth
  • VI is condensed with acetylene dimagnesium halide, preferably the bromide, followed by hydrolysis of the resulting product using an acidic hydrolyzing agent, e.g., a dilute solution of a mineral acid, preferably sulfuric acid, an aqueous solution of ammonium chloride, etc., followed by dehydration of the hydrolyzed product using a dehydrating agent, e.g., a lower alkanol solution of a hydrogen halide such as ethanolic hydrogen chloride solution, a dilute solution of H 80 in a lower alkanol, POCl in pyridine, etc., to yield 15,15'-dehydrozeaxanthin'dimethyl ether (VII).
  • VII is hydrogenated in the presence of a lead-palladium-calcium carbonate catalyst to form transzeaxanthin dirnethyl ether (VIII).
  • the reaction mixture is allowed to cool to room temperature, and 2 liters of ice Water and 2 liters of petroleum ether (3060 C.) are added and thoroughly mixed.
  • the water layer is separated and extracted with 1 liter of petroleum ether.
  • the water layer is discarded and the petroleum ether layers combined and washed six times, each time with 1 liter of 5% sulfuric acid; then with 1 liter of 5% sodium carbonate; and lastly with 1 liter of water.
  • the petroleum ether is removed under the vacuum of a Water pump, leaving 345 g. of crude product which is distilled under high vacuum using an oil pump. 199 g. of 4-(2,6,6 trimethyl 1,3 cyclohexadien-l-yl) 3-buten-2-one (H) distilling at 86 C. at 0.2 mm. pressure is obtained.
  • the resulting solution is stirred at room temperature under a blanket of nitrogen vfor 22 hours.
  • the solution is then cooled to 25 C. and 20 ml. of a 10% solution of zinc chloride in ethyl acetate is added all at once.
  • 152 ml. of freshly distilled ethyl vinyl other is dropped in at -10 C. during the course of 1.5 hours.
  • the reaction is stirred under nitrogen for 10 hours at room temperature.
  • 84 g. of sodium acetate, 720 ml. of glacial acetic acid, and 72 ml. of water are added in the order named and the mixture heated with stirring to C.
  • the condenser is fitted for distillation and the heating and stirring continued for two hours. During this time 150 ml.
  • the solution is then cooled to 10 C. and 5 ml. of a 10% solution of zinc chloride in ethyl acetate is added.
  • 30 cc. of freshly distilled ethyl propenyl ether is dropped in during the course of 1 hour at a temperature maintained in the range of 0 to 10 C.
  • the cooling bath is removed and the stirring continued for 10 hours.
  • 14 g. of sodium acetate, ml. of glacial acetic acid, and 15 ml. of Water are added in the order named.
  • the condenser is fixed for distillation and the reaction stirred at 95-100 C. for 2 hours. 37 ml. of the distillate results which is discarded.
  • the reaction mixture is cooled, diluted with 200 ml.
  • the reaction mixture is then poured onto ice and acidified with 5% sulfuri acid.
  • the ether layer is separated, washed with sodium bicarbonate, and then with water until neutral.
  • the ether layer is then dried over anhydrous calcium sulfate and the solvent removed under vacuum.
  • the residue, a pale yellow waxy solid is then dissolved in 1200 ml. of ether and 300 m1. of methanol.
  • To the resulting mixture is added 300 ml. of a solution of 6 N hydrogen chloride in isopropyl alcohol. The mixture is stirred for 10 minutes and then maintained at C. for 10 hours.
  • the resulting solids are filtered in an inert atmosphere and washed successively with sodium bicarbonate solution, water, and cold methanol.
  • the solids are crystallized from benzene to yield 36.1 g. of 15,15 dehydrozeaxanthin dimethyl ether (VII); melting point 147 C.
  • a process for preparing 4-(2,6,6 trimethyl 4- methoxy 1 cyclohexen 1 yl) 3 buten-Z-one (III) from B-ionone comprising (a) reacting fl-ionone with N-bromosuccinimide and dehydrobrominating the reaction product with a dehydrobrominating agent to yield 4-(2,6,6 trimethyl- 1,3-cyclohexadien-1-yl)-3-buten-2-one (H) and (b) treating (II) with methyl sulfate to form III.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

United States Patent 3,354,218 PRUCES FOR PREPARING 4-(2,6,6-TRIMETHYL-4- METHGXY 1 CYCLOHEXEN 1 YL) 3 BU- TEN-2-ONE Joseph Donald Surmatis, West Caldwell, NJ., assignor to I-Iofimann-La Roche Inc., Nutley, N.J., a corporation of New Jersey No Drawing. Filed May 10, 1963, Ser. No. 279,617 2 Claims. (Cl. 260-586) This application is a continuation-in-part application of copending application Ser. No. 198,724, filed May 31, 1962, now abandoned.
The present invention relates to a novel process for the preparation of zeaxanthin dimethyl ether.
Zeaxanthin dimethyl ether is useful as a coloring agent for coloring feedstuifs and foodstuffs. It is a known compound, having been prepared from natural zeaxanthin.
The present process is a process for its total synthesis. The instant process is carried out by first treating fi-ionone (I) with N-bromosuccinimide, followed by dehydrobromination of the reaction product with a dehydrobrominating agent such as dimethylaniline, pyridine, or other organic bases as diethylaniline, quinoline, etc. to form 4-(2, 6,6-trimethyl 1,3-cyclohexadien-l-yl)-3-buten-2-one (II). II is treated with methyl sulfate and methyl alcohol to form 4* (2,6,6-trimethy1-4-methoxy- 1 -cyclohexen-1 -yl -3-buten- 2-one (III). II is reacted with ethyl haloacetate, preferably ethyl chloroacetate, by the Darzens reaction to give 4 (2,6,6 trimethyl 4 methoxy-l-cyclohexen-l-yl)-2- methyl-Lbuten-Lal (IV). IV is treated with triethylortho- I II CHaO l CHaO VII 3,354,218 Patented Nov. 21, 1967 ice formate and phosphoric acid, followed by zinc chloride in ethyl acetate and ethyl vinyl ether and the resulting product is hydrolyzed with an acid hydrolyzing agent, e.g., a dilute solution of a mineral acid such as HCl, H o-phosphoric acid, etc., or a strong organic acid, preferably acetic acid in the presence of sodium acetate to form 6 (2,6,6 trimethyl 4-methoxy-l-cyclohexen-l-yl)-4- methyl-2,4-hexadien-l-al (V). V is treated with triethylorthoform-ate and phosphoric acid followed by treatment with zinc chloride in ethyl acetate and ethyl propenyl ether and the resulting product is hydrolyzed with an acid hydrolyzing agent, e.g., a dilute solution of a mineral acid such as HCl, H 80 o-phosphoric acid, etc., or a strong organic acid, preferably acetic acid in the presence of sodium acetate, to form 8-(2,6,6-trimethy1-4-meth0Xyl cyclohexen 1 yl)-2,6-dimethyl-2,4,6-octatriene-l-al (VI). VI is condensed with acetylene dimagnesium halide, preferably the bromide, followed by hydrolysis of the resulting product using an acidic hydrolyzing agent, e.g., a dilute solution of a mineral acid, preferably sulfuric acid, an aqueous solution of ammonium chloride, etc., followed by dehydration of the hydrolyzed product using a dehydrating agent, e.g., a lower alkanol solution of a hydrogen halide such as ethanolic hydrogen chloride solution, a dilute solution of H 80 in a lower alkanol, POCl in pyridine, etc., to yield 15,15'-dehydrozeaxanthin'dimethyl ether (VII). VII is hydrogenated in the presence of a lead-palladium-calcium carbonate catalyst to form transzeaxanthin dirnethyl ether (VIII).
The reaction scheme is given below:
CHO
VIII
(a) Preparation of 4-(2,6,6-trimeth l-I,3-cyclhexadien- 1-yl)-3-buten-2-0ne (II) 366 g. of fl-ionone (I) is placed in a -liter flask fitted with a stirrer, thermometer, and nitrogen inlet tube. To this are added 2.5 liters of carbon tetrachloride, 200 g. of sodium bicarbonate, 160 g. of calcium oxide, and 428 g. of N-bromosuccini-mide, in the order named. The reaction mixture is heated with stirring to a temperature of 72 C. and the heating source removed. The temperature continues to rise to 80 C. At this temperature vigorous reflux commences which lasts for about minutes. Stirring is continued until the temperature drops to 60 C. Then 550 ml. of dimethylaniline is added to the reaction mixture, and the mixture cooled to C. The solid is filtered off by suction with a glass sintered funnel and carefully washed with additional carbon tetrachloride. The carbon tetrachloride is removed from the filtrate under the vacuum of a water pump. The residue is heated with stirring under a blanket of nitrogen for 2 hours at 90-95 C. The residue is allowed to cool to C. and 180 ml. of pyridine are added. The mixture is heated with stirring to 90-95 C. and held at this temperature for an additional hour. The reaction mixture is allowed to cool to room temperature, and 2 liters of ice Water and 2 liters of petroleum ether (3060 C.) are added and thoroughly mixed. The water layer is separated and extracted with 1 liter of petroleum ether. The water layer is discarded and the petroleum ether layers combined and washed six times, each time with 1 liter of 5% sulfuric acid; then with 1 liter of 5% sodium carbonate; and lastly with 1 liter of water. The petroleum ether is removed under the vacuum of a Water pump, leaving 345 g. of crude product which is distilled under high vacuum using an oil pump. 199 g. of 4-(2,6,6 trimethyl 1,3 cyclohexadien-l-yl) 3-buten-2-one (H) distilling at 86 C. at 0.2 mm. pressure is obtained.
(b) Preparation of 4-(2,6,6-trimethyl-4-methoxy-1 cyclOhexen-I-yl) -3-baten-2-0ne (III) 72 cc. of concentrated sulfuric acid are added to 1800 ml. of methyl alcohol in a 5-liter flask fitted with a stirrer and a thermometer. The solution is cooled to 25 C. and 180 g. of 4-(2,6,6 trimethyl 1,3 cyclohexadien-lyl)-3-buten-2-one (II) added all at once. The solution is stirred under a blanket of nitrogen for 25 hours at a temperature of 2-5 C. and the reaction mixture is treated with 1800 cc. of ice water. Then with vigorous stirring, 250 cc. of 50% sodium hydroxide is added. The stirring is continued for an additional 30 minutes and the product extracted with 2 liters of petroleum ether (3060 C.). The petroleum ether layer is washed twice, each time with 1 liter of water, dried over anhydrous calcium sulfate, and the solvent removed by distillation under the vacuum of a water pump. 195 g. of crude product is obtained which is distilled at 80-86 C. at 0.08 mm. pressure to yield 104 g. of 4 (2,6,6 trimethyl 4 methoxyl-cyclohexen-l-yl 3 buten-2-one (III (c) Preparation of 4-(2,6,6-trimethyl-4-meth0xy-1- cyclohexen-I-yl) Z-methyl-Z-buten-I-al (IV) In a 3-liter, B-necked flask fitted with a stirrer, thermometer, and nitrogen inlet tube are placed 98.5 g. of 4-(2,6,6 trimethyl 4 methoxy 1 cyclohexen l-yl) 3-buten-2-one (III). 145 g. of ethyl chloracetate, and 46 ml. of methyl alcohol. The resulting solution is cooled to 20 C. and 81 g. of sodium methylate added in small portions over the period of 1 hour. The temperature is maintained at 6 to -10 C. during the addition. The reaction mixture is then stirred under a blanket of nitro' gen for minutes at 0 C. The temperature is lowered to 5 C., and the solution consisting of 60 g. of sodium hydroxide in 420 ml. of methanol is poured in all at once causing the temperature to rise to 20 C. Stirring is continued at this temperature for 45 minutes. The reaction mixture is cooled to 10 C. and 1150 ml. of ice water are added. The mixture is stirred for 1 hour and the product extracted 3 times, each time with 500 ml. of petroleum ether (boiling point 30-60 C.). The petro leum ether extracts are combined, washed with water,
dried over anhydrous calcium sulfate, and the solvent re-' ((1) Preparation of 6- (2 ,6 ,6-trim ethyl-4 meth oxy-I cycl 0 hexen-l-yl) 4-methyl-2,4-hexadien-1al (V) In a 2-liter flask fitted with a mechanical stirrer, condenser, thermometer, and nitrogen inlet tube is placed 200 g. of 4-(2,6,6 trimethyl 4 methoxy l cyclohexen- 1 yl) 2 methyl 2 buten l-al (IV). 160 ml. of triethylorthoformate, and 2 ml. of 85% phosphoric acid. The resulting solution is stirred at room temperature under a blanket of nitrogen vfor 22 hours. The solution is then cooled to 25 C. and 20 ml. of a 10% solution of zinc chloride in ethyl acetate is added all at once. Then 152 ml. of freshly distilled ethyl vinyl other is dropped in at -10 C. during the course of 1.5 hours. The reaction is stirred under nitrogen for 10 hours at room temperature. Then 84 g. of sodium acetate, 720 ml. of glacial acetic acid, and 72 ml. of water are added in the order named and the mixture heated with stirring to C. The condenser is fitted for distillation and the heating and stirring continued for two hours. During this time 150 ml. of distillate is obtained, which is discarded. The cooled reaction mixture is diluted with 2 liters of water and extracted 3 times, each time with 500 ml. of benzene. The benzene extracts are combined, washed with water, and concentrated under vacuum to a syrup. 251 g. of crude product is obtained. Upon crystallization from petroleum ether, 133 g. of 6-(2,6,6-trimethyl 4-methoxyl-cyclohexen-Lyl)-4-methyl-2,4-hexadien-l-al (V) is obtained as a pale yellow crystalline solid melting at 72 C. Upon furtherrecrystallization from petroleum other an analyticaly pure sample is obtained; melting point 78 C.
(e) Preparation of 8-(2,6,6-trimetlzyl-4-methOxy-Icyclo- Izexen-l-yl) 2,6-dimethyl-2,4,6-0ctatriene-1al (VI) In a 1-liter flask there are placed 53 g. of 6-(2,6,6-trimethyl 4 methoxy 1 cyclohexen 1 yl)-4-methyl- 2,4-hexadien-1-al (V), 30 ml. of triethylorthoformate, and 0.5 ml. of 85% phosphoric acid dissolved in 20 ml. of triethylorthoformate. The resulting solution is stirred at room temperature under a blanket of nitrogen for 60 hours. The solution is then cooled to 10 C. and 5 ml. of a 10% solution of zinc chloride in ethyl acetate is added. 30 cc. of freshly distilled ethyl propenyl ether is dropped in during the course of 1 hour at a temperature maintained in the range of 0 to 10 C. The cooling bath is removed and the stirring continued for 10 hours. Then 14 g. of sodium acetate, ml. of glacial acetic acid, and 15 ml. of Water are added in the order named. The condenser is fixed for distillation and the reaction stirred at 95-100 C. for 2 hours. 37 ml. of the distillate results which is discarded. The reaction mixture is cooled, diluted with 200 ml. of Water, and extracted three times, each time with 200 ml. of petroleum ether. The extracts are combined, washed with water, dried over anhydrous calcium sulfate and concentrated to a syrup under vacuum. 70 g. of 8-(2,6,6 trimethyl 4 methoxy-l-cyclohexen 1 yl 2,6 dimethyl 2,4,6 octatriene-1-al (V1) is obtained, which is purified by vacuum distilla- 5 tion yielding 48.4 g. of product; boiling point 94 C. at 6 microns. The sample is crystallized from petroleum ether; melting point 42 C.
(f) Preparation of 15,I5'-dehydr0zeaxanthin dimethyl ether (VII) Acetylene dimagnes'ium bromide is prepared by bubbling dry acetylene for 20 hours into a Grignard reagent reagent prepared from 38.8 g. of magnesium, 162 g. of ethyl bromide, and 620 ml. of ether. Then a solution of 120 g. of 8-(2,6,6 trimethyl 4 imethoxy 1 cyclohexen 1 yl) 2,6 dimethyl 2,4,6 octatriene-l-al (VI) in 500 ml. of ether is added rapidly and the solution heated at reflux for 2 hours. The reaction mixture is then poured onto ice and acidified with 5% sulfuri acid. The ether layer is separated, washed with sodium bicarbonate, and then with water until neutral. The ether layer is then dried over anhydrous calcium sulfate and the solvent removed under vacuum. The residue, a pale yellow waxy solid, is then dissolved in 1200 ml. of ether and 300 m1. of methanol. To the resulting mixture is added 300 ml. of a solution of 6 N hydrogen chloride in isopropyl alcohol. The mixture is stirred for 10 minutes and then maintained at C. for 10 hours. The resulting solids are filtered in an inert atmosphere and washed successively with sodium bicarbonate solution, water, and cold methanol. The solids are crystallized from benzene to yield 36.1 g. of 15,15 dehydrozeaxanthin dimethyl ether (VII); melting point 147 C.
(g) Preparation of trans-zeaxanthin dimethyl ether VIII) A suspension of 27 g. of 15,15'-dehydrozeaxanthin dimethyl ether (VII) in 300 ml. of petroleum ether is hydrogenated in the presence of 2.5 g. of lead-palladiumcalcium carbonate catalyst and 2.5 ml. of quinoline in petroleum ether until 1 molar equivalent of hydrogen is consumed. The suspension is then heated to the boiling point, the catalyst filtered 013?, and the catalyst washed thoroughly with additional portions of hot petroleum ether. The solvents are removed from the filtrate until a pasty mass remains, and the pasty mass heated at 90 6 C. for 16 hours. The solvent is filtered 011 and the precipitate recrystallized from benzene to give 19 g. of trans-zeaxanthin dimethyl ether (VIII); melting point 176 C.
Variations in the process of the invention can be undertaken by those skilled in the art without departing from the scope or spirit of the invention.
I claim:
1. A process for preparing 4-(2,6,6 trimethyl 4- methoxy 1 cyclohexen 1 yl) 3 buten 2 one (III) from 4-(2,6,6 trimethyl 1,3 cyclohexadien-lyl)-3-buten-2-one (II) comprising treating (II) with methyl sulfate to form III.
2. A process for preparing 4-(2,6,6 trimethyl 4- methoxy 1 cyclohexen 1 yl) 3 buten-Z-one (III) from B-ionone comprising (a) reacting fl-ionone with N-bromosuccinimide and dehydrobrominating the reaction product with a dehydrobrominating agent to yield 4-(2,6,6 trimethyl- 1,3-cyclohexadien-1-yl)-3-buten-2-one (H) and (b) treating (II) with methyl sulfate to form III.
References Cited UNITED STATES PATENTS 2,730,549 1/1956 Isler et a1 260598 2,819,298 1/1958 Isler et al 260598 2,871,267 1/ 1959 Petracek et a1. 2,898,385 8/1959 Isler et a1.
2,987,550 6/1961 Stieg et a1. 260598 3,068,292 12/1962 Reedy et a1 260598 FOREIGN PATENTS 843,438 8/1960 Great Britain.
OTHER REFERENCES Wagner et 211.: Synthetic Organic Chemistry, pp. 232-3 1953 BERNARD HELFIN, Primary Examiner.
L. ZITVER, Examiner.
L. WEINBERGER, Assistant Examiner.
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,354,218 November 21, 1967 Joseph Donald Surmatis It is certified that error appears in the above identified patent and that said Letters Patent are hereby corrected as shown below:
Column 1, line 28, "II is reacted" should read III is reacted Column 2, formula III should appear as shown below Column 3, line 70, "chloracetate" should read chloroacetate Column 4, line 46, "analyticaly" should read analytical Column 5, lines 8 and 9, cancel "reagent", second occurrence.
Signed and sealed this 3rd day of March 1970.
(SEAL) we; Attest:
EDWARD M.FLETCHER,JR. WILLIAM E. SCHUYLER, JR Attesting Officer Commissioner of Patents

Claims (1)

1. A PROCESS FOR PREPARING 4-(2,6,6 - TRIMETHYL - 4METHOXY - 1 - CYCLOHEXEN - 1 -YL) - 3 - BUTEN - 2 - ONE (III) FROM 4-(2,6,6 - TRIMETHYL - 1,3 - CYCLOHEXADIEN-1YL)-3-BUTEN-2-ONE (II) COMPRISING TREATING (II) WITH METHYL SULFATE TO FORM III.
US279617A 1963-05-10 1963-05-10 Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one Expired - Lifetime US3354218A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US279617A US3354218A (en) 1963-05-10 1963-05-10 Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US279617A US3354218A (en) 1963-05-10 1963-05-10 Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one

Publications (1)

Publication Number Publication Date
US3354218A true US3354218A (en) 1967-11-21

Family

ID=23069728

Family Applications (1)

Application Number Title Priority Date Filing Date
US279617A Expired - Lifetime US3354218A (en) 1963-05-10 1963-05-10 Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one

Country Status (1)

Country Link
US (1) US3354218A (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1807568A1 (en) * 1967-11-09 1969-06-19 Firmenich & Cie Unsaturated cycloaliphatic ketones
US3892809A (en) * 1971-09-13 1975-07-01 Firmenich & Cie Process for the preparation of butenoyl 1,3-cyclohexadienes
US3928455A (en) * 1971-06-14 1975-12-23 Hoffmann La Roche (2,6,6-Trimethyl-4-oxo-cyclohex-2-en-1-ylidene)-6-hydroxy-3-methyl-7-methylene-oct-2-ene-4-yne
US3931326A (en) * 1967-11-09 1976-01-06 Firmenich Sa Alkenoyl-cyclohexadienes
US3941841A (en) * 1971-06-14 1976-03-02 Hoffmann-La Roche Inc. Method for synthesizing rhodoxanthin
WO2004011423A2 (en) * 2002-07-29 2004-02-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050009758A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050009930A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050065096A1 (en) * 2002-07-29 2005-03-24 Lockwood Samuel Fournier Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050075316A1 (en) * 2002-07-29 2005-04-07 Lockwood Samuel Fournier Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050090469A1 (en) * 2002-07-29 2005-04-28 Lockwood Samuel F. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050113372A1 (en) * 2002-07-29 2005-05-26 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050261254A1 (en) * 2004-04-14 2005-11-24 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060088904A1 (en) * 2004-10-01 2006-04-27 Lockwood Samuel F Methods for the synthesis of astaxanthin
WO2006102576A1 (en) * 2005-03-23 2006-09-28 Cardax Pharmaceuticals, Inc. Water-dispersible carotenoids, including analogs and derivatives

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2730549A (en) * 1953-06-29 1956-01-10 Hoffmann La Roche Preparation of a polyene aldehyde
US2819298A (en) * 1955-07-22 1958-01-07 Hoffmann La Roche Process for the manufacture of carotenoids
US2871267A (en) * 1956-06-28 1959-01-27 California Inst Res Found beta-carotene derivatives and method of preparing derivatives of polyenes
US2898385A (en) * 1954-12-17 1959-08-04 Hoffmann La Roche Preparation of 15,15'-dehydro-beta-carotene
GB843438A (en) * 1957-11-08 1960-08-04 Hoffmann La Roche The manufacture of ú•ú¾ú´zeaxanthine compounds
US2987550A (en) * 1958-09-25 1961-06-06 Pfizer & Co C Process for the manufacture of c14 aldehyde
US3068292A (en) * 1960-03-23 1962-12-11 Eastman Kodak Co Oxygenated polyene aldehydes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2730549A (en) * 1953-06-29 1956-01-10 Hoffmann La Roche Preparation of a polyene aldehyde
US2898385A (en) * 1954-12-17 1959-08-04 Hoffmann La Roche Preparation of 15,15'-dehydro-beta-carotene
US2819298A (en) * 1955-07-22 1958-01-07 Hoffmann La Roche Process for the manufacture of carotenoids
US2871267A (en) * 1956-06-28 1959-01-27 California Inst Res Found beta-carotene derivatives and method of preparing derivatives of polyenes
GB843438A (en) * 1957-11-08 1960-08-04 Hoffmann La Roche The manufacture of ú•ú¾ú´zeaxanthine compounds
US2987550A (en) * 1958-09-25 1961-06-06 Pfizer & Co C Process for the manufacture of c14 aldehyde
US3068292A (en) * 1960-03-23 1962-12-11 Eastman Kodak Co Oxygenated polyene aldehydes

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1807568A1 (en) * 1967-11-09 1969-06-19 Firmenich & Cie Unsaturated cycloaliphatic ketones
US3931326A (en) * 1967-11-09 1976-01-06 Firmenich Sa Alkenoyl-cyclohexadienes
US3928455A (en) * 1971-06-14 1975-12-23 Hoffmann La Roche (2,6,6-Trimethyl-4-oxo-cyclohex-2-en-1-ylidene)-6-hydroxy-3-methyl-7-methylene-oct-2-ene-4-yne
US3941841A (en) * 1971-06-14 1976-03-02 Hoffmann-La Roche Inc. Method for synthesizing rhodoxanthin
US3892809A (en) * 1971-09-13 1975-07-01 Firmenich & Cie Process for the preparation of butenoyl 1,3-cyclohexadienes
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
WO2004011423A2 (en) * 2002-07-29 2004-02-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US20040162329A1 (en) * 2002-07-29 2004-08-19 Lockwood Samuel Fournier Structural carotenoid analogs for the inhibition and amelioration of disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050009758A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050009930A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050037995A1 (en) * 2002-07-29 2005-02-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050065097A1 (en) * 2002-07-29 2005-03-24 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050065096A1 (en) * 2002-07-29 2005-03-24 Lockwood Samuel Fournier Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050075316A1 (en) * 2002-07-29 2005-04-07 Lockwood Samuel Fournier Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050090469A1 (en) * 2002-07-29 2005-04-28 Lockwood Samuel F. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050113372A1 (en) * 2002-07-29 2005-05-26 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7317008B2 (en) 2002-07-29 2008-01-08 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
WO2004011423A3 (en) * 2002-07-29 2004-05-06 Hawaii Biotech Inc Structural carotenoid analogs for the inhibition and amelioration of disease
JP2010248243A (en) * 2002-07-29 2010-11-04 Cardax Pharmaceuticals Inc Structural carotenoid analogue for inhibition and amelioration of disease
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
JP2006517197A (en) * 2002-07-29 2006-07-20 ハワイ バイオテック, インコーポレイテッド Structural carotenoid analogues for disease control and amelioration
US7145025B2 (en) 2002-07-29 2006-12-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7592449B2 (en) 2002-07-29 2009-09-22 Cardax Pharmaceuticals, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7691901B2 (en) 2004-04-14 2010-04-06 Cardax Pharmaceuticals Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20050261254A1 (en) * 2004-04-14 2005-11-24 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060088904A1 (en) * 2004-10-01 2006-04-27 Lockwood Samuel F Methods for the synthesis of astaxanthin
US7247752B2 (en) 2004-10-01 2007-07-24 Cardax Pharmaceuticals, Inc. Methods for the synthesis of astaxanthin
US20060183185A1 (en) * 2004-10-01 2006-08-17 Lockwood Samuel F Method for the synthesis of astaxanthin
US20060178538A1 (en) * 2004-10-01 2006-08-10 Lockwood Samuel F Methods for the synthesis of chiral dihydroxy intermediates useful for the chiral synthesis of carotenoids
US20060167319A1 (en) * 2004-10-01 2006-07-27 Lockwood Samuel F Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids
US20060155150A1 (en) * 2004-10-01 2006-07-13 Lockwood Samuel F Methods for the synthesis of lutein
US20060111580A1 (en) * 2004-10-01 2006-05-25 Lockwood Samuel F Methods for the synthesis of chiral dihydroxy ketone intermediates useful for the chiral synthesis of carotenoids
US20060088905A1 (en) * 2004-10-01 2006-04-27 Lockwood Samuel F Methods for the synthesis of zeazanthin
WO2006102576A1 (en) * 2005-03-23 2006-09-28 Cardax Pharmaceuticals, Inc. Water-dispersible carotenoids, including analogs and derivatives

Similar Documents

Publication Publication Date Title
US3354218A (en) Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one
US3754016A (en) Novel cycloalkenone esters
US3687990A (en) Isoprenoid compounds and a process for producing the same
Cope et al. The Introduction of Substituted Vinyl Groups. I. Isopropenyl Alkyl Malonic Esters
US3489806A (en) Isoprenoid compounds and a process for producing the same
US3978100A (en) Allenic esters, process for preparation thereof and process for rearrangement thereof
US3072709A (en) Octahydronaphthaleneones, alcohols and their acyl derivatives
US3558712A (en) Method for the synthesis of zeaxanthins,xanthophylis,and 3-oxo-beta carotene
US3679754A (en) {67 -ionone derivatives and process therefor
US2382085A (en) Synthesis of vitamin a
US3974181A (en) Trimethyl-1,4-dioxaspiro[4,5]dec-7-en-8-methanol
US2369163A (en) Synthesis of vitamin a
US3184516A (en) Thiapyrans and their use in preparing polyenes
US2819312A (en) Process for the manufacture of polyene aldehydes
US3156714A (en) Syntheses of spirilloxanthin and intermediates
US3624105A (en) Method for synthesizing rhodoxanthin
US2898375A (en) Cyclic ketones and process for preparing intermediates therefor
US2410463A (en) Methods of preparing stilbene derivatives
US2369164A (en) Synthesis of vitamin a
US2531567A (en) Derivatives of cyclohexene and process of preparing same
US3466331A (en) Intermediate for synthesizing rhodoxanthin
US4009202A (en) 2(or 3)-methyl-1-acetoxy-4-alkoxy (or phenoxy)-1,3-butadienes
US2676990A (en) Method of making vitamin a and intermediates formed thereby
US2369162A (en) Synthesis of vitamin a
US2879303A (en) Process for the manufacture of polyene compounds